Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation & immunology (I&I), today announced that it will present a late-breaking oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.
https://mma.prnewswire.com/media/1679488/Marengo_Therapeutics_Logo.jpg
The presentation will include initial Phase 2 monotherapy results from the ongoing STARt-001 trial, which is evaluating Invikafusp alfa in tissue-agnostic, tumor mutational burden-high (TMB-H) advanced cancers. The findings underscore Invikafusp alfa's potential to selectively activate unique T cell subsets, leading to reinvigoration of anti-tumor immunity across a broad range of solid tumors.
Presentation Details:
— Title: Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR B-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a Phase 1/2 trial
— Conference: SITC Annual Meeting 2025
— Abstract Number: LBA1316
— Session Title: Clinical Oral Abstract Session 1
— Session Date and Time: Friday, November 7, 2025, 11:30 AM ET
— Presenter: Aurélien Marabelle, MD, PhD (Gustave Roussy Cancer Center, France)
Marengo will also present datafrom its TriSTAR T cell engager platform in addition to four preclinical analyses in collaboration with the National Cancer Institute (NCI) exploring rational combinations of Invikafusp alfa with standard-of-care modalities.
About Marengo Therapeutics Marengo Therapeutics, Inc., a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets of the germline TCR repertoire to provide lifelong protection against cancer and autoimmune diseases. With a passionate team of dedicated scientists experienced in immunology and oncology, and three proprietary platforms: Selective T Cell Activation Repertoire (STAR), Trispecific T Cell Engager (Tri-STAR) and T cell Depletor (MSTAR), Marengo is working to selectively target the right T cells in the right patients to create a world in which everyone's immune system can defeat cancer and autoimmune diseases. To learn more, visit marengotx.com.
About the STAR™ Platform Marengo's STAR™ Platform is a multi-specific antibody-fusion platform derived from Marengo's proprietary library of antibodies targeting germline-encoded variable VB regions of the TCR fused to different T cell co-stimulatory moieties. Combining a novel non-clonal mode of TCR activation with a T cell co-stimulator in the same molecule promotes a distinct mechanism of action that promotes durable anti-tumor VB T cell responses
About Invikafusp alfa (STAR0602) Invikafusp alfa (STAR0602) is the lead candidate from Marengo's STAR™ platform. It is designed to selectively activate a common VB T cell subset found in all cancers by combining a non-clonal mode of TCR activation with a T cell co-stimulatory signal in a single molecule. This innovative approach promotes the expansion of clonally diverse, effector memory VB T cells, enhancing anti-tumor immunity and enabling durable tumor clearance. Extensive preclinical studies demonstrate STAR0602's potent anti-tumor activity in both mouse and human ex vivo models via a novel mechanism of action.
About the STARt-001 Clinical Study
STARt-001 is a global Phase 1/2 clinical trial evaluating the safety, tolerability, and preliminary efficacy of invikafusp alfa as a monotherapy in biomarker-selected patients with advanced antigen-rich solid tumors, including PD-1 refractory and rare tumor types. The trial consists of two parts: Phase 1 dose escalation and Phase 2 dose expansion. For more information, visit clinicaltrials.gov(Identifier: NCT05592626).
Patients interested in participating in this study at the National Cancer Institute (NCI) can contact NCI's toll-free number: 1-800-4-CANCER (1-800-422-6237) (TTY: 1-800-332-8615), visit the website at https://trials.cancer.gov, or email NCIMO_referrals@mail.nih.gov.
Marengo Contacts:
MediaPeg Rusconi I peg.rusconi@deerfieldgroup.com
InvestorsSvetlana Makhni | smakhni@marengotx.com
https://edge.prnewswire.com/c/img/favicon.png?sn=PH11816&sd=2025-10-31
View original content to download multimedia:https://www.prnewswire.com/news-releases/marengo-to-present-late-breaking-clinical-oral-abstract-at-sitc-2025-highlighting-initial-monotherapy-activity-of-invikafusp-alfa-in-tissue-agnostic-tmb-high-advanced-cancers-302600621.html
SOURCE Marengo Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=PH11816&Transmission_Id=202510310700PR_NEWS_USPR_____PH11816&DateId=20251031